# The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study

> **NCT05453448** · NA · COMPLETED · sponsor: **Xiangya Hospital of Central South University** · enrollment: 272 (actual)

## Conditions studied

- Antiviral Drugs

## Interventions

- **DRUG:** tenofovir alafenamide
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT05453448
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-05-30
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453448, "The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05453448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*